SKYE - Skye Bioscience, Inc. Common Stock

Recent News

Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data - Skye Bioscience ( NASDAQ:SKYE )

Benzinga • 1 week, 3 days ago • score: 0.24

Nimacimab plus tirzepatide led to 40%+ weight loss in preclinical obesity studies. Nimacimab reduced post-treatment rebound weight gain by more than 50%. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On On Thursday, Skye Bioscience Inc.

Neutral

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

GlobeNewswire • 1 month, 2 weeks ago • score: 0.02

SAN DIEGO, July 30, 2025 ( GLOBE NEWSWIRE ) -- Skye Bioscience, Inc. ( Nasdaq: SKYE ) ( "Skye" ) , a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Thursday, August 7, 2025 at ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Skye Bioscience, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapeutic drugs that modulate the endocannabinoid system. The company is headquartered in San Diego, California.

52W High

$7.11

52W Low

$1.14

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

2.34

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-2.56

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

2.84

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

1.44%

Institutions (25–75% balanced)

66.11%

Shares Outstanding

30,988,400

Float

18,620,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

EPS (TTM)

-1.06

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.73%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Value

N/A

Trend

—

Signal Cross

No cross

As of

—